These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 2358719)
1. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers]. Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719 [TBL] [Abstract][Full Text] [Related]
2. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer]. Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644 [TBL] [Abstract][Full Text] [Related]
3. Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer. Inoue M; Nakanishi K; Ueda G; Tanizawa O Am J Clin Oncol; 1992 Feb; 15(1):1-6. PubMed ID: 1550076 [TBL] [Abstract][Full Text] [Related]
4. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer]. Kobayashi H; Hayata T; Terao T; Kawashima Y Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816 [TBL] [Abstract][Full Text] [Related]
5. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors]. Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
8. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]. Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214 [TBL] [Abstract][Full Text] [Related]
9. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer]. Chen YL; Liu YQ; Tang DH; Chu CN Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749 [TBL] [Abstract][Full Text] [Related]
10. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; RodinĂ² C; Soldani M; Tonato M; Finardi C Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230 [TBL] [Abstract][Full Text] [Related]
11. [An analysis of factors influential in improving the survival rate of patients with ovarian cancer]. Ohta M; Tomoda Y; Kano T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1008-15. PubMed ID: 2730004 [TBL] [Abstract][Full Text] [Related]
12. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer]. Li M; Huang X Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C. Sawada M; Yamasaki M; Urabe T; Ozaki M; Yanagita T; Takayama K; Taki I Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):315-21. PubMed ID: 2099727 [TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563 [TBL] [Abstract][Full Text] [Related]
15. [Metastatic brain tumor after chemotherapy of ovarian cancer]. Fukuda K; Chen JT; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Sakamoto A Gan No Rinsho; 1987 Jan; 33(1):115-8. PubMed ID: 3102810 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of advanced ovarian cancer]. de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer]. Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005 [TBL] [Abstract][Full Text] [Related]
20. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract]. Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]